CLINICAL_TRIALS
trial_result
· 2012-06-29
Clinical Trial Update: OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients [Phase 3]
Summary
Phase 3 trial of OraVescent Fentanyl for breakthrough pain in opioid-tolerant cancer patients has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cephalon | Conditions: Pain, Cancer | Phase 3 | Status: COMPLETED